S M Kerruish

Learn More
In a longitudinal study of the evolution of serum beta 2-microglobulin (beta 2-m) levels in 37 patients with myelomatosis, those patients with a level of < 4 mg/l at first presentation had a median survival of 46 months, whereas those with an initial level of > mg/l had a median survival of 15 months. THe beta 2-m appeared to be independent of the level of(More)
Changes in serum-beta 2-microglobulin (beta 2-m) levels were measured in 52 patients with chronic lymphocytic leukaemia during periods of observation of 5-43 months. While the majority of patients had elevated levels (> 3 mg/l), higher values tended to be associated with more advanced disease as assessed clinically. Patients with nonprogressive,(More)
Serum beta2-microglobulin measurements were made in Burkitt lymphoma and nasopharyngeal carcinoma in Africans and infectious mononucleosis in Europeans. There was a significant increase of beta2-microglobulin levels in active Burkitt tumour compared to those in remission but young West African children have higher levels than that in Caucasians.(More)
  • 1